How the Novo Nordisk Board Tackled Weight-Loss Drug Demand

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Add to basket failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Adding to library failed

Please try again

Follow podcast failed

Unfollow podcast failed

How the Novo Nordisk Board Tackled Weight-Loss Drug Demand

Listen for free

View show details

A deep dive into how the board of Novo Nordisk managed the explosive demand for its GLP-1 weight-loss drugs like Ozempic and Wegovy, navigating supply shortages, manufacturing investments, and pricing debates. Lucas and Luna unpack the specific decisions at the board level that allowed a Danish insulin maker to become Europe's most valuable company. They discuss the tension between long-term patient trust and short-term profit, the board's role in forecasting demand, and the ethical questions that come with selling a drug that could reshape public health. #NovoNordisk #Ozempic #Wegovy #GLP1 #WeightLossDrugs #Pharmaceuticals #BoardOfDirectors #CorporateGovernance #SupplyChain #Manufacturing #DrugPricing #Healthcare #BusinessStrategy #Business #FexingoBusiness #BoardroomConversations #BusinessPodcast #Leadership Keep every episode free: buymeacoffee.com/fexingo

No reviews yet